| Title： | Consensus of Chinese experts on the pharmaceutical service for taxane anticancer drugs |
| Edition： | Original |
| Classification： | Experts consensus |
| Field： | Treatment |
| Countries and regions： | China |
| Guidelines users： | |
| Evidence classification method： | Relevant literatures on domestic and foreign guidelines, consensuses, and clinical studies were collected regularly to form a knowledge system for taxane anticancer drugs, and the GRADE method was used to score the collected evidence. At the same time, we coordinate the professional and clinicians to form an expert group, regularly exchange relevant clinical experience, and reach a consensus through the evaluation and optimization of the Delphi method. |
| Development unit： | National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College |
| Registration time: | 2022-05-23 |
| Registration number： | IPGRP-2022CN287 |
| Purpose of the guideline: |
